Korean J Dermatol.
2016 Nov;54(9):739-743.
Bortezomib-induced Histiocytoid Sweet Syndrome
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea. bellotte@hanmail.net
Abstract
- Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper extremities, face, and neck. The incidence of Sweet syndrome in the general population is unknown because of limited reports on this condition. Bortezomib, an antineoplastic agent that is the standard of care for multiple myeloma, has been reported to be associated with Sweet syndrome. We describe the case of a 66-year-old man who developed bortezomib-induced histiocytoid Sweet syndrome during treatment for multiple myeloma.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Malignancy-associated Histiocytoid Sweet Syndrome in a Patient with AML
- Histiocytoid Sweet Syndrome in a Child without Underlying Systemic Disease
- A Case of Sweet Syndrome Induced by Bortezomib Rechallenge
- A Case of Histiocytoid Sweet's Syndrome with Myelodysplastic Syndrome
- A Case of Histiocytoid Sweet Syndrome Developed in the Patient with Pure White Cell Aplasia
